Get the Stockscreener App
1.135
0.88%
0.005
Synlogic Inc stock is traded at $1.135, with a volume of 113.
It is up +0.88% in the last 24 hours and up +2.16% over the past month.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
See More
Previous Close:
$1.13
Open:
$1.135
24h Volume:
113
Relative Volume:
0.01
Market Cap:
$13.28M
Revenue:
$3.37M
Net Income/Loss:
$-57.28M
P/E Ratio:
-0.1056
EPS:
-10.7522
Net Cash Flow:
$-51.83M
1W Performance:
+0.44%
1M Performance:
+2.16%
6M Performance:
-20.28%
1Y Performance:
-28.75%
1-Day Range:
$1.135
$1.135
1-Week Range:
$1.0735
$1.14
52-Week Range:
$0.898
$1.88
Synlogic Inc Stock (SYBX) Company Profile
Name
Synlogic Inc
Sector
Industry
Phone
617-659-2802
Address
PO BOX 30, WINCHESTER, MA
Compare SYBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYBX
Synlogic Inc
|
1.135 | 12.98M | 3.37M | -57.28M | -51.83M | -10.75 |
|
ONC
Beigene Ltd Adr
|
240.68 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.92 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.84 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.77 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Synlogic Inc Stock (SYBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-21-19 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-19 | Initiated | Jefferies | Buy |
| Dec-13-18 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-18 | Initiated | H.C. Wainwright | Buy |
| Jan-29-18 | Initiated | Piper Jaffray | Overweight |
View All
Synlogic Inc Stock (SYBX) Latest News
Synlogic (NASDAQ:SYBX) Stock Passes Below Two Hundred Day Moving Average – What’s Next? - Defense World
Synlogic (SNDX) to Attend Meeting Hosted by B. Riley in New York - GuruFocus
Synlogic (SYBX) Projected to Post Earnings on Tuesday - Defense World
Renaissance Technologies LLC Decreases Stake in Synlogic, Inc. (NASDAQ:SYBX) - Defense World
5 Best Microbiome Companies (May 2025) - Securities.io
Synlogic’s executive Mary Beth Dooley sells $172 in common stock - Investing.com Australia
Synlogic’s executive Mary Beth Dooley sells $172 in common stock By Investing.com - Investing.com UK
SYBX stock touches 52-week low at $1.14 amid market challenges - Investing.com India
Gallium Arsenide Market Applications and Semiconductor Industry Impact - openPR.com
Synlogic (NASDAQ:SYBX) Shares Pass Below Fifty Day Moving Average – Here’s Why - Defense World
SYBX stock touches 52-week low at $1.15 amid market challenges - Investing.com Australia
Synlogic (SYBX) to Release Quarterly Earnings on Tuesday - Defense World
Synlogic Inc. (SYBX) reports earnings - Quartz
Week Ahead (Nov.2226): FDA Decision, Data Presentations (ABEO, SYBX, AADI…) - RTTNews
CRISPR and Cas Gene Market May Set a New Epic Growth Story | Fate Therapeutics, Cellectis, Synlogic - Newstrail
Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
Synlogic's executive sells shares worth $2,802 - MSN
Synlogic's executive sells shares worth $2,802 By Investing.com - Investing.com South Africa
Promising Growth Expected in Gout Therapeutics Market, Set to Reach $5.03 Billion by 2029 with a CAGR of 11.7% - WhaTech
Synlogic (SYBX) Stock Price, News & Analysis - MarketBeat
Synlogic announces board member resignation By Investing.com - Investing.com Canada
Synlogic announces board member resignation - Investing.com
The definitive Boston biotech layoff tracker for 2024 - The Business Journals
Fmr LLC Trims Stock Holdings in Synlogic, Inc. (NASDAQ:SYBX) - Defense World
Biopolymers Market to Reach USD 47.4 Billion by 2032 Driven - GlobeNewswire
Synlogic (NASDAQ:SYBX) Trading Down 0.7% – What’s Next? - Defense World
Only the paranoid survive, and the CEO’s paradox, from Aoife Brennan - BioCentury
Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Synlogic (FRA:MIN) 3-Year FCF Growth Rate : 21.90% (As of Sep. 2024) - GuruFocus.com
Synlogic (FRA:MIN) Momentum Rank : 2 (As of Nov. 30, 2024) - GuruFocus.com
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Rising Disease Prevalence Driving Revenue, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve
Synlogic Third Quarter 2024 Earnings: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023) - Yahoo Finance
Synlogic Reports Q3 2024 Financial Outcomes - TipRanks
Synlogic Reports Third Quarter 2024 Financial Results - GlobeNewswire
The 2024 Biotech Graveyard - Fierce Biotech
Synlogic's head of finance Mary Beth Dooley sells $110 in stock - Investing.com
(PDF) The effects of caffeinated and decaffeinated coffee on sex hormone-binding globulin and endogenous sex hormone levels: A randomized controlled trial - ResearchGate
Oxygen Scavenger Market Set to Reach USD 8.2 Billion by - GlobeNewswire
Synlogic says co entered into sales agreement with Cowen And Company, LLC - Reuters
Urea Cycle Disorders Treatment Market Research In New Report - WhaTech
Synlogic Reports Second Quarter 2024 Financial Results - GlobeNewswire
Otsuka snaps up Jnana with its phenylketonuria drug for $800m - Pharmaceutical Technology
Xilio Therapeutics Appoints Aoife Brennan and James Shannon to its Board of Directors - citybiz
Gut Microbiota Market Set to Reach a Staggering US$ 3,600.1 Million by 2032 - BioSpace
Synlogic Reports First Quarter 2024 Financial Results - GlobeNewswire
Designer Genes: Synlogic Is Crafting Living Therapeutics Programmed to Treat Disease: - Mary Ann Liebert, Inc.
Human Microbiome Market Size & Share to Surpass USD 2,555 million by 2030 - WhaTech
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
Synlogic Announces Top Executive Departures and Compensation Deals - TipRanks
Synlogic adopts shareholder rights plan, eyes strategic options By Investing.com - Investing.com India
Synlogic Inc Stock (SYBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Synlogic Inc Stock (SYBX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dooley Mary Beth | See Remarks below |
Feb 03 '25 |
Sale |
1.33 |
2,107 |
2,802 |
13,045 |
| Dooley Mary Beth | Head of Finance |
Oct 29 '24 |
Sale |
1.40 |
79 |
111 |
15,152 |
0.61%
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):